There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
ACADEMIA
Skills for Clinical Studies Required to Become Authorized Hypertension Specialist: JSH
The Japanese Society of Hypertension (JSH) will require that doctors have the necessary skills for conducting clinical studies in order to become authorized as a hypertension specialist, and it will set up a committee this year to discuss measures for…
To read the full story
ACADEMIA
- Japan Pediatric Society Recommends COVID Jab for Ages 5-17
August 12, 2022
- High Hopes for Sanofi’s Enjaymo as Japan’s First CAD Therapy: Osaka University Professor
August 5, 2022
- 7 Japan Scientific Societies Issue Proposal on Development of Vaccines, Anti-Infectives
August 3, 2022
- Deregulation Likely to Create 1.15 Trillion Yen Headroom for Switched OTC Growth: Health Economist
July 15, 2022
- Gynecologist Cautious about Inclusion of Pregnant Women in Clinical Trials, but Says ICH Move Will Spark Safety Discussions
July 14, 2022
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…